Clinical trial
A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers
NCT04174118 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 24, 2019
- Completion date
- March 6, 2023
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.